This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
According to the KRYSTAL-1 study, the KRASG12c inhibitor adagrasib, also known as MRTX849, is largely well tolerated and shows considerable efficacy in patients with non–small cell lung cancer harboring this mutation. The drug is also active, albeit more modestly, in colorectal cancer and several other solid tumor types.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
December 2020
Volume 10, Issue 12
Volume 10, Issue 12
Another KRAS Inhibitor Holds Its Own
Jump to section
Advertisement